Canadian researchers develop a cell-free DNA-based multimodal assay for early cancer detection in patients with Li-Fraumeni Syndrome, a high-cancer-risk condition. The assay outperforms conventional methods, promising more sensitive and less invasive cancer surveillance.
BioNTech reports early survival data for VEGF bispecific, weeks after buying Chinese partner
Last month, BioNTech went all-in on VEGF bispecific antibodies. On Tuesday, to validate its bet, the company shared early survival data from … Sign up